Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Simultaneous Delivery of Wharton’S Jelly Mesenchymal Stem Cells and Insulin-Like Growth Factor-1 in Acute Myocardial Infarction



Rabbani S1 ; Soleimani M2 ; Sahebjam M1 ; Imani M3 ; Haeri A4 ; Ghiaseddin A5 ; Nassiri SM6 ; Ardakani JM1 ; Rostami MT1 ; Jalali A1 ; Tafti SHA1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Hematology, Tarbiat Modares University, Tehran, Iran
  3. 3. Iran polymer and petrochemical institute, Tehran, Iran
  4. 4. Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Biomedical Engineering Division, Chemical Engineering Department, Tarbiat Modares University, Tehran, Iran
  6. 6. Faculty of veterinary medicine, University of Tehran, Tehran, Iran

Source: Iranian Journal of Pharmaceutical Research Published:2018

Abstract

Wharton’s jelly mesenchymal stem cells (HWJMSCs) hold promise for myocardial regeneration, but optimal treatment regimen (preferably with a growth factor) is required to maximize functional benefits. The aim of this study was to explore the cardioprotective and angiogenesis effects of HWJMSCs combined with insulin-like growth factor-1 (IGF-1) in the treatment of acute myocardial infarction. The hydrogel consisted of Polyethylene glycol (PEG) and hyaluronic acid was prepared and characterized with regards to rheology, morphology, swelling, degradation, and release behaviors. To examine in-vivo effects, the hydrogels containing HWJMSCs either alone (Cells/hydrogel group) or with IGF-1 (Cells/hydrogel/IGF-1 group) were intra-myocardially injected into a rabbit myocardial infarction model. In-vivo efficacy was evaluated histological, immunohistochemical, echocardiography, scanning electron microscopy, and SPECT analyses. Eight weeks after infusion, the Cells/hydrogel and Cells/hydrogel/IGF-1 groups exhibited significantly increased left ventricular ejection fraction by echocardiography. Percent of ejection fraction was respectively 18.5% and 40% greater than control (P < 0.01). Vascular density (CD31 positive cells) of both treatment groups were more than the control group and this superiority was more remarkable in Cells/hydrogel/IGF-1 group. Cells/hydrogel/IGF-1 group showed the least defect size in SPECT analysis. Combinatory therapy with HWJMSCs and IGF-1 may additionally improve cardiac function and promote angiogenesis. © 2018, Iranian Journal of Pharmaceutical Research. All rights reserved.
Related Docs
1. Regenerative Strategies for the Consequences of Myocardial Infarction: Chronological Indication and Upcoming Visions, Biomedicine and Pharmacotherapy (2022)
2. Stem Cells and Heart Tissue Regeneration, Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges (2020)
3. Controlled Anti-Cancer Drug Release Through Advanced Nano-Drug Delivery Systems: Static and Dynamic Targeting Strategies, Journal of Controlled Release (2020)
4. A Thermo-Sensitive Hydrogel Composed of Methylcellulose/Hyaluronic Acid/Silk Fibrin As a Biomimetic Extracellular Matrix to Simulate Breast Cancer Malignancy, European Polymer Journal (2022)
Experts (# of related papers)
View all Related Experts
Mahmoud Azami (1)
Shahram Rabbani (1)